Wu Yanheng, Gu Wenyi, Li Li, Chen Chen, Xu Zhi Ping
Australian Institute for Bioengineering and Nanotechnology, the University of Queensland, St. Lucia 4072, QLD, Australia.
School of Biomedical Sciences, the University of Queensland, St. Lucia 4072, QLD, Australia.
Nanomaterials (Basel). 2019 Jan 28;9(2):159. doi: 10.3390/nano9020159.
Suitable carriers are crucial to RNAi applications for cancer genotherapy and T-cell immunotherapy. In this research, we selected two extensively-investigated biocompatible inorganic nanoparticle carriers, i.e., layered double hydroxide (LDH) and lipid-coated calcium phosphate (LCP) and then compared their efficacy for siRNA delivery in T cells, in order to understand which carrier is more efficient in delivering functional programmed cell death protein 1 siRNA (PD-1 siRNA) to suspended T lymphocytes. Both LDH and LCP nanoparticles quickly delivered gene segment to mouse T cell lines (EL4), while the LCP nanoparticles exhibited more cellular uptake and higher PD-1 gene silence efficiency. We further demonstrated that LCP nanoparticles successfully reduced the expression of PD-1 in human ex vivo tumor infiltrating lymphocytes (TILs). Thus, LCP nanoparticles can be used as a better nano-carrier for gene therapy in lymphocytes, especially in regards to TIL-related cancer immunotherapy.
合适的载体对于癌症基因治疗和T细胞免疫治疗的RNA干扰应用至关重要。在本研究中,我们选择了两种经过广泛研究的生物相容性无机纳米颗粒载体,即层状双氢氧化物(LDH)和脂质包被的磷酸钙(LCP),然后比较它们在T细胞中递送小干扰RNA(siRNA)的效果,以了解哪种载体在将功能性程序性细胞死亡蛋白1小干扰RNA(PD-1 siRNA)递送至悬浮T淋巴细胞方面更有效。LDH和LCP纳米颗粒均能快速将基因片段递送至小鼠T细胞系(EL4),而LCP纳米颗粒表现出更多的细胞摄取和更高的PD-1基因沉默效率。我们进一步证明,LCP纳米颗粒成功降低了人离体肿瘤浸润淋巴细胞(TILs)中PD-1的表达。因此,LCP纳米颗粒可作为淋巴细胞基因治疗的更好纳米载体,特别是在与TIL相关的癌症免疫治疗方面。